TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast Limited has appointed James M. O’Brien as its new Chief Financial Officer, a strategic move as the company transitions to a fully integrated commercial organization. O’Brien’s extensive experience in financial management within the life sciences and pharmaceutical industries is expected to bolster Mesoblast’s financial leadership, aiding in the commercialization of its products and potential expansion into new markets.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform to create therapies that respond to severe inflammation, offering significant reductions in inflammatory processes. Mesoblast’s product Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and the company is expanding its cell therapy offerings to other inflammatory diseases and conditions.
YTD Price Performance: -28.39%
Average Trading Volume: 4,906,603
Technical Sentiment Signal: Buy
Current Market Cap: A$2.85B
Learn more about MSB stock on TipRanks’ Stock Analysis page.